Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + capecitabine versus capecitabine alone in treatment-resistant gastric cancer
IRCT20240622062212N1Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab and capecitabine in gastric cancer (GC) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Quality of Life and Overall Survival. Started Dec 2025; status: completed.
02
Drugs
pembrolizumabcapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on IRCT20240622062212N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240622062212N1.